Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Centers for Disease Control, Department of Health and Human Services.
Maintenance dialysis can be continued in patients with end stage renal disease who have manifestations of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) [now known as the human immunodeficiency virus], including the acquired immunodeficiency syndrome, or who are positive for antibody to HTLV-III/LAV. These patients can be dialyzed in hospital-based or free-standing dialysis units using conventional infection-control precautions. Transmission of HTLV-III/LAV is adequately prevented by standard blood and body fluid precautions, and disinfection and sterilization procedures.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000914:Antibodies, Viral / Q000032:analysis; D003428:Cross Infection / Q000517:prevention & control*; D017977:Deltaretrovirus / Q000276:immunology; D004203:Disinfection / Q000592:standards; D015483:HIV Antibodies; D006280:Health Workforce; D006801:Humans; D009784:Occupational Diseases / Q000517:prevention & control; D010530:Peritoneal Dialysis / Q000592:standards; D006435:Renal Dialysis / Q000592:standards*
D000914:Antibodies, Viral; D015483:HIV Antibodies